Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX – Get Free Report) shares reached a new 52-week low during trading on Saturday . The stock traded as low as $13.61 and last traded at $13.61, with a volume of 112377 shares changing hands. The stock had previously closed at $16.15.
Wall Street Analysts Forecast Growth
Several brokerages have weighed in on TLX. UBS Group lifted their target price on Telix Pharmaceuticals Limited American Depositary Shares from $21.00 to $22.00 and gave the company a “buy” rating in a research note on Monday, January 27th. William Blair reaffirmed an “outperform” rating on shares of Telix Pharmaceuticals Limited American Depositary Shares in a report on Wednesday, March 12th.
Read Our Latest Research Report on TLX
Telix Pharmaceuticals Limited American Depositary Shares Stock Performance
About Telix Pharmaceuticals Limited American Depositary Shares
Telix Pharmaceuticals Ltd. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.
Read More
- Five stocks we like better than Telix Pharmaceuticals Limited American Depositary Shares
- What is a Low P/E Ratio and What Does it Tell Investors?
- Newsmax’s IPO Whiplash: Meme Stock Hype or Growth Potential?
- What is the S&P 500 and How It is Distinct from Other Indexes
- Disney 2025 Shareholders: Major Updates for Investors
- Expert Stock Trading Psychology Tips
- Advance Auto Parts Stock: A Classic Rebound Play in the Making
Receive News & Ratings for Telix Pharmaceuticals Limited American Depositary Shares Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Telix Pharmaceuticals Limited American Depositary Shares and related companies with MarketBeat.com's FREE daily email newsletter.
